Efficacy and safety of liraglutide, a once‐daily human glucagon‐like peptide‐1 receptor agonist, in African‐American people with Type 2 diabetes: a meta‐analysis of sub‐population data from seven phase III trials

AIM: To evaluate the efficacy and safety of the glucagon‐like peptide‐1 (GLP‐1) receptor agonist liraglutide in African‐American people with Type 2 diabetes. METHODS: Analyses were performed on patient‐level data from individuals self‐defined as African‐American or non‐African‐American in seven phas...

Descripción completa

Detalles Bibliográficos
Autores principales: Shomali, M. E., Ørsted, D. D., Cannon, A. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5248619/
https://www.ncbi.nlm.nih.gov/pubmed/27412701
http://dx.doi.org/10.1111/dme.13185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5248619/
https://www.ncbi.nlm.nih.gov/pubmed/27412701
http://dx.doi.org/10.1111/dme.13185

Ejemplares similares